Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Langer

Showing results (11-20 of 686) with videos related to

Pageof 69
Sort By:
Oncology (Williston Park, N.Y.)|July 17, 2004
Irinotecan in advanced lung cancer: focus on North American trialsCorey J Langer
Expert Opinion on Investigational Drugs|October 27, 2004
CT-2103: emerging utility and therapy for solid tumoursCorey J Langer
Clinical Lung Cancer|December 9, 2003
Irinotecan/Taxane combinations in advanced non-small-cell lung cancerCorey J Langer
Supportive Cancer Therapy|July 18, 2008
Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case reportCorey J Langer
Oncology (Williston Park, N.Y.)|August 11, 2001
The emerging world role of irinotecan in lung cancerC J Langer
Current Treatment Options in Oncology|June 12, 2002
Elderly patients with lung cancer: biases and evidenceCorey J Langer
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLCCorey J Langer
American Journal of Clinical Oncology|April 2, 2014
Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitorsCorey J Langer
Drugs|March 11, 2000
The role of tegafur/uracil in pulmonary malignancyC J Langer
Seminars in Oncology|November 24, 1999
Induction or neoadjuvant therapy in resectable non-small cell lung cancerC J Langer
Pageof 69

Showing results (11-20 of 686) with videos related to

Sort By:
Pageof 69
Oncology (Williston Park, N.Y.)|July 17, 2004
Irinotecan in advanced lung cancer: focus on North American trialsCorey J Langer
Expert Opinion on Investigational Drugs|October 27, 2004
CT-2103: emerging utility and therapy for solid tumoursCorey J Langer
Clinical Lung Cancer|December 9, 2003
Irinotecan/Taxane combinations in advanced non-small-cell lung cancerCorey J Langer
Supportive Cancer Therapy|July 18, 2008
Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case reportCorey J Langer
Oncology (Williston Park, N.Y.)|August 11, 2001
The emerging world role of irinotecan in lung cancerC J Langer
Current Treatment Options in Oncology|June 12, 2002
Elderly patients with lung cancer: biases and evidenceCorey J Langer
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLCCorey J Langer
American Journal of Clinical Oncology|April 2, 2014
Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitorsCorey J Langer
Drugs|March 11, 2000
The role of tegafur/uracil in pulmonary malignancyC J Langer
Seminars in Oncology|November 24, 1999
Induction or neoadjuvant therapy in resectable non-small cell lung cancerC J Langer
Pageof 69